Custom Drugs in Spotlight: FDA Info Collection Feedback
Published Date: 2/23/2026
Notice
Summary
The FDA is asking for public feedback on how it collects information about drug compounding, where pharmacists mix medicines just for patients who need them. This helps keep these special medicines safe and effective while making sure patients can still get them. Comments are open until March 25, 2026, so pharmacists and facilities should weigh in soon!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
503A Pharmacy Reporting and Recordkeeping Burden
Pharmacies that compound under section 503A have reporting and recordkeeping duties. FDA estimates 45 respondents with ~197 reports each (8,879 total annual responses) at 0.87 hours per response (7,968 total hours) for 503A reporting, plus 503A recordkeeping estimated at 90 responses at 1 hour each (90 total hours).
Adverse Event Reporting and Recordkeeping
Outsourcing facilities must submit adverse event reports under section 503B(b)(5) in accordance with 21 CFR 310.305(e)(1), generally within 15 calendar days with 15-day follow-ups as needed, and must maintain adverse event records for 10 years. FDA estimates 503B AER reporting covers 55 respondents with 55 total AERs (average 1.10 hours each = 61 hours) and associated recordkeeping estimated at 880 hours (55 respondents × 16 hours). Reports must be submitted electronically using Form FDA 3500A (OMB control number 0910-0291).
503B Outsourcing Facility Reporting Burden
If you operate or register an outsourcing compounding facility under section 503B, you must submit reports identifying the drugs you compound as required by sections 503B(b)(1)–(3). FDA estimates this activity covers about 75 respondents making ~108 reports each (8,111 total annual responses) at an average 0.2 hours per response, totaling 214 hours annually.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2026-03447, Self-Regulatory Organizations; MIAX Emerald, LLC; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change To Amend Exchange Rule 531 To Establish the New Purge Liquidity Taker Event Report
MIAX Emerald is rolling out a new optional report called the Purge Liquidity Taker Report for Market Makers. This update tweaks Exchange Rule 531 to help traders get clearer info on liquidity takers. The change is effective immediately, aiming to boost transparency without extra costs right now.
Next: 2026-03449, Self-Regulatory Organizations; New York Stock Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change for Amendments to Rule 7.35A and Rule 7.35C
The New York Stock Exchange is updating how it calculates prices during opening and trading halt auctions to make them more accurate. These changes affect traders and market makers who rely on these auctions to set fair prices. The new rules took effect right after filing on February 6, 2026, aiming to improve market fairness without changing fees.